Personalized healthcare (PH) aims to improve patients’ lives and reduce global mortality, key targets of the sustainable development goal 3 (SDG3). PH includes the association of patients genetic and biochemistry characteristics with the accurate, early, rapid and highly efficient diagnostic and therapeutic approaches. Development of PH, affordable to most countries, requires some breakthroughs in bioengineering and biotechnology for regenerative medicine, medical imaging and drug engineering.
To provide the promise of PH it is key to improve the quality and performance of diagnosis by setting accurate and non-invasive imaging and to set new biosensor devices for monitoring early biomarkers. Innovative diagnostic tools must be accompanied by the development of curative therapeutic strategies that circumvent the current unmet need. In this regard, improvement in artificial organs from 3D bioprinting and stem cells, and the increase in the number of safe drugs that can administrated in a convenient and painless manner via oral, skin, nose and other routes, are essential.
This Article Collection aims at gathering primary research articles, data notes and reviews dealing with the latest progress and applications of magnetic resonance imaging (MRI) and single, photon emission computed tomography (SPECT), development of biosensors, functional nanostructured materials, interfaces and devices, regenerative medicine, 3D organ bioprinting, the basic and translational inducible pluripotent stem cells research. We strongly encourage submission of in vitro, preclinical and clinical research with multidisciplinary, interdisciplinary and translational approaches.
Potential topics include, but are not limited to
- Functional and quantitative MRI and SPECT
- MRI and SPECT images reconstruction
- Artificial organs
- Regenerative medicine
- Biomaterials
- Nanotechnology
- Stem cells
- Bioengineering
- Nanomedicine
- Theranostics
Amar Abderrahmani, [email protected], IEMN, CNRS 8520, Faculty of Medicine, Lille University (Editor-in-Chief All Life, https://think.taylorandfrancis.com/meet-the-editor-of-all-life/) Dr. Amar ABDERRAHMANI (AA) is Full Professor of Cell and Molecular Biology at the Faculty of Medicine at Lille University. He has a multidisciplinary background including a PhD and pharmacy graduation in Molecular genetics and pharmaceutical chemistry. AA has been honoured by several Swiss awards and in 2011, of National Chair of Excellence in beta-cell biology, bioscience and diabetes. AA has been member of several scientific committees of Diabetes Association and is currently Editor-in-Chief of All Life.
Disclosure Statement: AA declares no conflicts of interest regarding this work.
